AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $206.00 price target on the stock.
Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period [Yahoo! Finance]
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy [Yahoo! Finance]
Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030 [Yahoo! Finance]
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? [Yahoo! Finance]